Bayer AG is to invest around EUR 48 million to expand its hexamethylene diisocyanate (HDI) capacities. A new building is currently under construction on a 3,000-square-meter site. The 35 meter-tall production facility with its adjacent tank farm is to go on stream in mid-2002 and will double the current capacity to 60,000 tpa. The company processes HDI – an important precursor for coating raw materials – into Desmodur® N, predominantly in Leverkusen and Dormagen. The largest field of application for these aliphatic polyisocyanates is in automotive coatings, but polyurethane systems are also being used increasingly in the construction sector and in the wood and furniture industry. The demands made on surface coatings with regard to appearance, chemical and mechanical resistance, lightfastness and weather stability are constantly growing. As a result, demand is mounting for aliphatic polyisocyanates for the formulation of high-performance polyurethane coatings. The Desmodur N grades based on HDI are the classic lightfast crosslinking agents for two-component polyurethane systems. Bayer produces these coating raw materials not only at its German sites in Leverkusen and Dormagen, but also in the United States, Brazil and Japan. Another production site in Asia is currently at the planning stage. According to Bernd Steinhilber, head of Industrial Coatings in Bayer's Coatings and Colorants Business Group, the main arguments for the expansion of the HDI facility in Leverkusen were "the good infrastructure of the site and its central position within Europe." In addition, the complete infrastructure of the existing HDI production plant can be used, because the two facilities will be separated only by a road running between them.
Bayer: Slow start to the year as expected
The Bayer Group experienced a slow start to 2023 as expected. “Sales were on a par with the exceptionally strong prior-year quarter,” CEO Werner Baumann said on Thursday when presenting the Quarterly Statement for the first quarter. The normalization in the glyphosate business has accelerat ... more
Bayer: Significant growth in sales and earnings
The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the challenging environment. We were able to deliver, even during these difficult times, and met the upgraded financial targets we set in Aug ... more
Bill Anderson to become CEO of Bayer AG
The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board of Management on April 1, 2023. Bill Anderson was elected unanimously after a thorough selection process which began mid last year. Werne ... more
Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of Bayer AG, an international health care, nutrition and innovative materials group based in Leverkusen, Germany. In North America, Bayer had 2006 net sales of 7.8 billion euros and employed 17,200 at year end. Bayer’s three s ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
